January 6, 2022 Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator Read More
December 8, 2021 H3 Biomedicine Presents Investigational Data Update on H3B-6545 for Treatment of Locally Advanced or Metastatic Estrogen Receptor- positive, HER2-negative Breast Cancer at San Antonio Breast Cancer Symposium Read More
October 8, 2021 H3 Biomedicine Presents Update on Intratumoral E7766 Clinical Program for Advanced Solid Tumors or Lymphomas at AACR-NCI-EORTC Conference Read More
Nature Communications | July 23, 2021 Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors Intron selection during the formation of prespliceosomes is a critical event in pre-mRNA splicing. Chemical modulation of intron selection has… Read More
May 20, 2021 H3 Biomedicine Announces Presentation of Four Abstracts at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Read More
February 11, 2021 H3 Biomedicine Announces Expanded Use of Real-World Evidence in Precision Medicine Research Read More
December 8, 2020 H3 Biomedicine, Inc. Presents Data Update on H3B-6545 for Treatment of Locally Advanced or Metastatic Estrogen Receptor-positive, HER2-negative Breast Cancer at San Antonio Breast Cancer Symposium Read More
ACS Medicinal Chemistry Letters | Dec. 2, 2020 Discovery of Aminopyrazole Derivatives as Potent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2 and 3 Fibroblast growth factor receptors (FGFR) 2 and 3 have been established as drivers of numerous types of cancer with multiple… Read More
Nature Communications | Apr. 29, 2020 Intron Retention Is a Hallmark and Spliceosome Represents a Therapeutic Vulnerability in Aggressive Prostate Cancer The role of dysregulation of mRNA alternative splicing (AS) in the development and progression of solid tumors remains to be… Read More